Protective efficacy of catalytic bioscavenger, paraoxonase 1 against sarin and soman exposure in guinea pigs

Biochemical Pharmacology

Volumn 81, Issue 6, 2011, Pages 800-809

  Valiyaveettil, Manojkumar ^a   Alamneh, Yonas ^a   Rezk, Peter ^b   Biggemann, Lionel ^a   Perkins, Michael W ^b   Sciuto, Alfred M ^b   Doctor, Bhupendra P ^a   Nambiar, Madhusoodana P ^a,c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Catalytic bioscavenger; Chemical warfare nerve agents; Paraoxonase 1; Sarin; Soman

Indexed keywords

ACETYLCHOLINESTERASE; ARYLDIALKYLPHOSPHATASE 1; CHOLINESTERASE; SARIN; SOMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BRAIN; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; GUINEA PIG; LETHALITY; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; PROPHYLAXIS; PULSE RATE; SURVIVAL RATE;

ANIMALS; ARYLDIALKYLPHOSPHATASE; BLOOD GAS ANALYSIS; BLOOD PRESSURE; CATALYTIC DOMAIN; FREE RADICAL SCAVENGERS; GUINEA PIGS; HUMANS; MALE; PROTECTIVE AGENTS; RABBITS; SARIN; SOMAN;

EID: 79951953915     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.12.024     Document Type: Article

References (60)

1. Aldridge WN, Davison AN. The mechanism of inhibition of cholinesterases by organophosphorus compounds. Biochem J 1953;55:763-6.
2. Flynn CJ, Wecker L. Elevated choline levels in brain. A non-cholinergic component of organophosphate toxicity. Biochem Pharmacol 1986;35:3115-21.
3. Bajgar J. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 2004;38:151-216.
4. Haigh JR, Johnston SR, Peters BM, Doctor BP, Gordon RK, Adler M, et al. Inhibition of guinea pig hemi-diaphragm acetylcholinesterase activity by pyridostigmine bromide and protection against soman toxicity. Chem Biol Interact 2005;157-158:381-2. (Pubitemid 41757693)
5. Kadriu B, Guidotti A, Costa E, Auta J. Imidazenil, a non-sedating anticonvulsant benzodiazepine, is more potent than diazepam in protecting against DFP-induced seizures and neuronal damage. Toxicology 2009;256:164-74.
6. Shih TM, Rowland TC, McDonough JH. Anticonvulsants for nerve agent-induced seizures: the influence of the therapeutic dose of atropine. J Pharmacol Exp Ther 2007;320:154-61. (Pubitemid 46025730)
7. Koplovitz I, Stewart JR. A comparison of the efficacy of HI6 and 2-PAM against soman, tabun, sarin, and VX in the rabbit. Toxicol Lett 1994;70:269-79. (Pubitemid 24049760)
8. Lenz DE, Maxwell DM, Koplovitz I, Clark CR, Capacio BR, Cerasoli DM, et al. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact 2005;157-158:205-10. (Pubitemid 41757652)
9. Doctor BP, Saxena A. Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 2005;157-158:167-71. (Pubitemid 41757647)
10. Doctor BP, Raveh L, Wolfe AD, Maxwell DM, Ashani Y. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci Biobehav Rev 1991;15:123-8.
11. Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci USA 2008;105:12780-4.
12. Costa LG, Cole TB, Vitalone A, Furlong CE. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 2005;352:37-47. (Pubitemid 40093856)
13. Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, et al. Paraoxonase 1 (PON1) status and risk of insecticide exposure. J Biochem Mol Toxicol 2005;19:182-3. (Pubitemid 40967291)
14. Mackness B, Beltran-Debon R, Aragones G, Joven J, Camps J, Mackness M. Human tissue distribution of paraoxonases 1 and 2 mRNA. IUBMB Life 2010;62:480-2.
15. Hashim Z, Ilyas A, Saleem A, Salim A, Zarina S. Expression and activity of paraoxonase 1 in human cataractous lens tissue. Free Radic Biol Med 2009;46:1089-95.
16. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507. (Pubitemid 26159866)
17. Josse D, Masson P. Human plasma paraoxonase (HuPON1): an anti-atherogenic enzyme with organophosphate hydrolase activity. Ann Pharm Fr 2001;59:108-18. (Pubitemid 32390647)
18. Furlong CE, Richter RJ, Chapline C, Crabb JW. Purification of rabbit and human serum paraoxonase. Biochemistry 1991;30:10133-40.
19. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 1991;30:10141-9.
20. Furlong CE, Costa LG, Hassett C, Richter RJ, Sundstrom JA, Adler DA, et al. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact 1993;87:35-48. (Pubitemid 23205360)
21. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6. (Pubitemid 23063292)
22. Costa LG, Cole TB, Furlong CE. Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. J Toxicol Clin Toxicol 2003;41:37-45. (Pubitemid 36268556)
23. Watson CE, Draganov DI, Billecke SS, Bisgaier CL, La Du BN. Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Pharmacogenetics 2001;11:123-34. (Pubitemid 32216123)
24. Otto TC, Harsch CK, Yeung DT, Magliery TJ, Cerasoli DM, Lenz DE. Dramatic differences in organophosphorus hydrolase activity between human and chimeric recombinant mammalian paraoxonase-1 enzymes. Biochemistry 2009;48:10416-22.
25. Otto TC, Kasten SA, Kovaleva E, Liu Z, Buchman G, Tolosa M, et al. Purification and characterization of functional human paraoxonase-1 expressed in Trichoplusia ni larvae. Chem Biol Interact 2010;187:388-92.
26. Valiyaveettil M, Alamneh Y, Biggemann L, Soojhawon I, Doctor BP, Nambiar MP. Efficient hydrolysis of the chemical warfare nerve agent tabun by recombinant and purified human and rabbit serum paraoxonase 1. Biochem Biophys Res Commun 2010;403:97-102.
27. Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 1995;76:219-26.
28. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-7. (Pubitemid 28335041)
29. Fu AL, Wang YX, Sun MJ. Naked DNA prevents soman intoxication. Biochem Biophys Res Commun 2005;328:901-5. (Pubitemid 40238722)
30. Cowan J, Sinton CM, Varley AW, Wians FH, Haley RW, Munford RS. Gene therapy to prevent organophosphate intoxication. Toxicol Appl Pharmacol 2001;173:1-6. (Pubitemid 32480359)
31. Duysen EG, Parikh K, Aleti V, Manne V, Lockridge O, Chilukuri N. Adenovirus-mediated human paraoxonase1 gene transfer to provide protection against the toxicity of the organophosphorus pesticide toxicant diazoxon. Gene Ther 2010. doi: 10.1038/gt.2010.136.
32. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000;10:767-79. (Pubitemid 32042829)
33. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 2009;235:1-9.
34. Gaidukov L, Bar D, Yacobson S, Naftali E, Kaufman O, Tabakman R, et al. In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes. BMC Clin Pharmacol 2009;9:18.
35. 4-induced liver injury. Toxicol Lett 2010;193:159-66.
36. Nambiar MP, Wright BS, Rezk PE, Smith KB, Gordon RK, Moran TS, et al. Development of a microinstillation model of inhalation exposure to assess lung injury following exposure to toxic chemicals and nerve agents in Guinea pigs. Toxicol Mech Methods 2006;16:295-306.
37. Nambiar MP, Gordon RK, Moran TS, Richards SM, Sciuto AM. A simple method for accurate endotracheal placement of an intubation tube in Guinea pigs to assess lung injury following chemical exposure. Toxicol Mech Methods 2007;17:385-92. (Pubitemid 47360091)
38. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 2001;354:1-7. (Pubitemid 32183437)
39. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6.
40. Che MM, Conti M, Boylan M, Sciuto AM, Gordon RK, Nambiar MP. Blood and bronchoalveolar lavage fluid acetylcholinesterase levels following microinstillation inhalation exposure to sarin in Guinea pigs. Inhal Toxicol 2008;20:821-8. (Pubitemid 352032216)
41. Perkins MW, Pierre Z, Rezk P, Sabnekar P, Kabra K, Chanda S, et al. Acute respiratory toxicity following inhalation exposure to soman in guinea pigs. Toxicol Appl Pharmacol 2010;245:171-8.
42. Ellman GL, Courtney KD, Andres Jr V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
43. Augustinsson KB, Eriksson H, Faijersson Y. A new approach to determining cholinesterase activities in samples of whole blood. Clin Chim Acta 1978;89:239-52. (Pubitemid 9030337)
44. Donovan DA, Zinkl JG. Modifications of a cholinesterase method for determination of erythrocyte cholinesterase activity in wild mammals. J Wildl Dis 1994;30:234-40.
45. Rezk PE, Graham JR, Moran TS, Gordon RK, Sciuto AM, Doctor BP, et al. Acute toxic effects of nerve agent VX on respiratory dynamics and functions following microinsillation inhalation exposure in guinea pigs. Inhal Toxicol 2007;19:291-302.
46. Katos AM, Conti M, Moran TS, Chon TW, Gordon RK, Sciuto AM, et al. Acute microinstillation inhalation exposure to soman induces changes in respiratory dynamics and functions in guinea pigs. Inhal Toxicol 2009;21:1-10.
47. Conti ML, Che MM, Boylan M, Sciuto AM, Gordon RK, Nambiar MP. Acute microinstillation inhalation exposure to sarin induces changes in respiratory dynamics and functions in guinea pigs. Int J Toxicol 2009;28:436-47.
48. Shih TM, Kan RK, McDonough JH. In vivo cholinesterase inhibitory specificity of organophosphorus nerve agents. Chem Biol Interact 2005;157-158:293-303.
49. Aharoni A, Gaidukov L, Yagur S, Toker L, Silman I, Tawfik DS. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci USA 2004;101:482-7. (Pubitemid 38084662)
50. Boado RJ, Hui EK, Lu JZ, Pardridge WM. CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein. Biotechnol Bioeng 2011;108:186-96.
51. Akgur SA, Ozturk P, Sozmen EY, Delen Y, Tanyalcin T, Ege B. Paraoxonase and acetylcholinesterase activities in humans exposed to organophosphorous compounds. J Toxicol Environ Health A 1999;58:469-74. (Pubitemid 30025752)
52. BenMoyal-Segal L, Vander T, Shifman S, Bryk B, Ebstein RP, Marcus EL, et al. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. FASEB J 2005;19:452-4. (Pubitemid 40316547)
53. Sklan EH, Lowenthal A, Korner M, Ritov Y, Landers DM, Rankinen T, et al. Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in health, risk factors, exercise training, and genetics study. Proc Natl Acad Sci USA 2004;101:5512-7. (Pubitemid 38481188)
54. Worek F, Aurbek N, Koller M, Becker C, Eyer P, Thiermann H. Kinetic analysis of reactivation and aging of human acetylcholinesterase inhibited by different phosphoramidates. Biochem Pharmacol 2007;73:1807-17. (Pubitemid 46601412)
55. Shafferman A, Ordentlich A, Barak D, Stein D, Ariel N, Velan B. Aging of somanyl-acetylcholinesterase adducts: facts and models. Biochem J 1997;324(Pt 3):996-8. (Pubitemid 27285563)
56. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;69:541-50.
57. Gouedard C, Barouki R, Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol 2004;24:2378-83. (Pubitemid 39658045)
58. Gouedard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 2003;63:945-56. (Pubitemid 36369002)
59. Boesch-Saadatmandi C, Egert S, Schrader C, Coumol X, Barouki R, Muller MJ, et al. Effect of quercetin on paraoxonase 1 activity-studies in cultured cells, mice and humans. J Physiol Pharmacol 2010;61:99-105.
60. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011;81:337-44.